IP Library › Granted Patent US 12,357,659
Granted Patent B2
US 12,357,659 · App. 17/488,820 · Granted Jul 15, 2025

Production of megakaryocytes or platelets from monocytes

Inventors: Zeev Estrov (Houston, TX); Srdan Verstovsek (Houston, TX); Taghi Manshouri (Houston, TX); Ivo Veletic (Houston, TX)
Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
A61K35/19A61P7/04C12N5/0644
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,659
App. No.
17/488,820
Granted
Jul 15, 2025
Kind
B2
Abstract

We disclose a method, comprising extracting cells from a tissue of a donor, wherein the tissue is selected from the group consisting of blood and bone marrow; isolating CD14 + monocytes from the extracted cells; culturing the isolated CD14 + monocytes; differentiating the cultured CD14 + monocytes into megakaryocytes; and administering, to a patient suffering from a platelet deficiency, at least one cell type selected from the group consisting of the differentiated megakaryocytes and platelets produced by the differentiated megakaryocytes. We also disclose a kit comprising at least one material usable in a method; and instructions to perform a method.

Claims (14)

1. A method of producing megakaryocytes, comprising:

extracting cells from a tissue of a donor, wherein the tissue is selected from the group consisting of blood and bone marrow;

isolating CD14 + /CD34 − monocytes from the extracted cells; and

culturing the isolated CD14 30 /CD34 − monocytes in vitro in the presence of thrombopoietin (TPO) for a sufficient time to permit differentiation of the CD14 + /CD34 − monocytes into megakaryocytes.

2. The method of claim 1 , wherein the sufficient time to permit differentiation is about 12 days or more.

3. The method of claim 1 , wherein culturing the isolated CD14 + /CD34 − monocytes in vitro is further in the presence of interleukin-3 (IL-3).

4. The method of claim 1 , wherein the culturing the isolated CD14 + /CD34 − monocytes in vitro is further in the presence of interleukin-6 (IL-6).

5. The method of claim 1 , wherein culturing the isolated CD14 + /CD34 − monocytes in vitro is further in the presence of a collagen.

6. The method of claim 1 , wherein the megakaryocytes are CD42b positive.

7. The method of claim 1 , wherein the megakaryocytes comprise multi-lobulated nuclei.

8. A method of producing platelets, the method comprising culturing the megakaryocytes produced by the method of claim 1 for a sufficient time to permit production of platelets.

9. The method of claim 8 , further comprising combining the platelets with at least one of a buffer, preservative, adjuvant, surfactant, or diluent.

10. The method of claim 1 , wherein the isolating is carried out using fluorescence-activated cell sorting (FACS) or a magnetic sorting column.

11. The method of claim 1 , further comprising combining the megakaryocytes with at least one of a buffer, preservative, adjuvant, surfactant, or diluent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2022
From: ESTROV, ZEEV; VERSTOVSEK, SRDAN; MANSHOURI, TAGHI; VELETIC, IVO
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 059774/0844 →
Continuity (2)
Provisional Application 63085114 · Sep 29, 2020
Related Publication 20220096556A1 · Mar 31, 2022
References Cited (39)
Mandl et al., Characterization of the CD14++CD16+ Monocyte Population in Human Bone Marrow, Plos One, 9(11): 1-6. (Year: 2014). [cited by examiner]
Pilling et al., Identification of Markers that Distinguish Monocyte-Derived Fibrocytes from Monocytes, Macrophages, and Fibroblasts, Plos One, 4(10): 1-18. (Year: 2018). [cited by examiner]
Mason et al., Assessing the value of autologous and allogeneic cells for regenerative medicine, Regen. Med., 4(6): 835-853. (Year: 2009). [cited by examiner]
Sleaseman et al. Immunomagnetic Selection of Purified Monocyte and Lymphocyte Populations from Peripheral Blood Mononuclear Cells following Cryopreservation, Clinai and Diagnostic Labratory Immunology, p. 653-658. (Year… [cited by examiner]
O'Grady et al., The long-term preservation of bone marrow, Transfusion, 12(5): 312-316. (Year: 1972). [cited by examiner]
Klairmont et al., The Comparative Sensitivity of Immunohistochemical Markers of Megakaryocytic Differentiation in Acute Megakaryoblastic Leukemia, Am J Clin Pathol, 150: 461-467. (Year: 2018). [cited by examiner]
Sirad et al., Expression of bcr-abl Abrogates Factor-Dependent Growth of Human Hematopoietic M07E Cells by an Autocrine Mechanism, Blood, 83(6): 1575-1585. (Year: 1994). [cited by examiner]
Casati et al., Refinement of the colony-forming unit-megakaryocyte (CFU-MK) assay for its application to pharmaco-toxicological testing, Toxicology in Vitro, 17: 69-75. (Year: 2003). [cited by examiner]
Hogge et al., Quantitation and characterization of human megakaryocyte colony-forming cells using a standardized serum-free agarose assay, 96: 790-800. (Year: 1997). [cited by examiner]
Noetzli et al., New Insights Into the Differentiation of Megakaryocytes From Hematopoietic Progenitors, Arterioscler Thromb Vasc Biol, 39: 1288-1300. (Year: 2019). [cited by examiner]
Nakasone et al. Increased CD83 expression of CD34-positive monocytes in donors during peripheral blood stem cell mobilization in humans. Sci Rep 9, 16499 (2019) (Year: 2019). [cited by examiner]
Bucala et al., “Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repai”, Molecular Medicine, vol. 1, No. 1, Nov. 1994, pp. 71-81. [cited by applicant]
Debili et al., “Different Expression of Cd41 on Human Lymphoid and Myeloid Progenitors From Adults and Neonates”, Blood, vol. 97, No. 7, May 2001, pp. 2023-2030. [cited by applicant]
Eaves , “Hematopoietic Stem Cells: Concepts, Definitions, and the New Reality”, Blood, vol. 125, No. 17, Apr. 23, 2015, pp. 2605-2613. [cited by applicant]
Groopman , “The Pathogenesis of Myelofibrosis in Myeloproliferative Disorders”, Annals of Internal Medicine, vol. 92, No. 6, Jun. 1980, pp. 857-858. [cited by applicant]
Hamers et al., “Human Monocyte Heterogeneity as Revealed by High-Dimensional Mass Cytometry”, Arteriosclerosis Thrombosis and Vascular Biology, vol. 39, No. 1, Jan. 2019, pp. 25-36. [cited by applicant]
Hopman et al., “Advances in Stem Cell Mobilization”, Blood Reviews, vol. 28, No. 1, Jan. 2014, pp. 31-40. [cited by applicant]
Husheem et al., “Characterization of Circulating Human Osteoclast Progenitors: Development of In Vitro Resorption Assay”, Calcified Tissue International, vol. 76, No. 3, Apr. 2005, pp. 222-230. [cited by applicant]
Kuwana et al., “Human Circulating CD14+ Monocytes as a Source of Progenitors That Exhibit Mesenchymal Cell Differentiation”, Journal of Leukocyte Biology, vol. 74, No. 5, Dec. 2003, pp. 833-845. [cited by applicant]
Law et al., “Analysis of Human Megakaryocytic Cells Using Dual-Color Immunofl Uorescence Labeling”, Cytometry, vol. 41, No. 4, Nov. 2000, 17 pages. [cited by applicant]
Lei et al., “Induction of Differentiation of Human Stem Cells Ex Vivo: Toward Large-scale Platelet Production”, World Journal of Stem Cells, vol. 11, No. 9, Sep. 2019, pp. 666-676. [cited by applicant]
Lundahl et al., “Monocyte and Neutrophil Adhesion to Matrix Proteins Is Selectively Enhanced in the Presence of Inflammatory Mediators”, Scandinavian Journal of Immunology, vol. 44, No. 2, Aug. 1996, pp. 143-149. [cited by applicant]
McLornan et al., “Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012”, British Journal of Haematology, vol. 157, No. 4, May 2012, pp. 413-425. [cited by applicant]
Nakamura et al., “Expandable Megakaryocyte Cell Lines Enable Clinically Applicable Generation of Platelets from Human Induced Pluripotent Stem Cells”, Cell Stem Cell, vol. 14, No. 4, Apr. 3, 2014, pp. 535-548. [cited by applicant]
Nowicka et al., “CyTOF Workflow: Differential Discovery in High-throughput High-Dimensional Cytometry Datasets”, vol. 6, No., Nov. 2017, 69 pages. [cited by applicant]
Passacquale et al., “Monocyte-Platelet Interaction Induces a ProInflammatory Phenotype in Circulating Monocytes”, Plos One, vol. 6, No. 10, Available online at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192052/pdf/p… [cited by applicant]
Prieto et al., “Regulated Expression of Integrins and Other Adhesion Molecules During Differentiation of Monocytes Into Macrophages”, Cellular Immunology, vol. 156, No., 1, Jun. 1994, pp. 191-211. [cited by applicant]
Quintas-Cardama et al., “Preclinical Characterization of Atiprimod, A Novel Jak2 and Jak3 Inhibitor”, Investigational New Drugs, vol. 29, No. 5, 2011, pp. 816-826. [cited by applicant]
Rampal et al., “Integrated Genomic Analysis Illustrates the Central Role of JAK-STAT Pathway Activation Inmyeloproliferative Neoplasm Pathogenesis”, Blood, vol. 123, No. 22, May 29, 2014, 17 pages. [cited by applicant]
Reilkoff et al., “Fibrocytes: Emerging Effector Cells in Chronic Inflammation”, Nature Reviews Immunology, vol. 11, No. 6, 2011, pp. 427-435. [cited by applicant]
Stack et al., “Multiplexed Immunohistochemistry, Imaging, and Quantitation: A Review, With an Assessment of Tyramide Signal Amplification, Multispectral Imaging and Multiplex Analysis”, Methods, vol. 70, No. 1, Sep. 201… [cited by applicant]
Stroncek et al., “Platelet Transfusions”, Lancet, vol. 370, Aug. 2007, pp. 427-438. [cited by applicant]
Thiele et al., “European Consensus on Grading Bone Marrow Fibrosis and Assessment of Cellularity”, Haematologica, vol. 90, No. 8, Apr. 2005, pp. 1128-1132. [cited by applicant]
Thiele et al., “Grade of Bone Marrow Fibrosis Is Associated With Relevant Hematological Findings—a Clinicopathological Study on 865 Patients With Chronic Idiopathic Myelofibrosis”, Annals of Hematology, vol. 85, No. 4, … [cited by applicant]
Vannucchi , “A Pathobiologic Pathway linking Thrombopoietin, GATA-1, and TGF-beta 1 in the Development of Myelofibrosis”, Blood, vol. 105, No. 9, May 1, 2005, pp. 3493-3501. [cited by applicant]
Vener et al., “Prognostic Implications of the European Consensus for Grading of Bone Marrow Fibrosis in Chronic Idiopathic Myelofibrosis”, Blood, vol. 111, No. 4, Feb. 15, 2008, pp. 1862-1865. [cited by applicant]
Verstovsek et al., “A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis”, The New England Journal of Medicine, vol. 366, No. 9, Mar. 1, 2012, pp. 799-807. [cited by applicant]
Verstovsek et al., “Role of Neoplastic Monocyte-derived Fibrocytes in Primary Myelofibrosis”, Journal of Experimental Medicine, vol. 213, No. 9, Aug. 2016, pp. 1723-1740. [cited by applicant]
Williamson et al., “Challenges in the Management of the Blood Supply”, The Lancet, vol. 381, May 2013, pp. 1866-1875. [cited by applicant]